从肿瘤精准医疗创新性临床试验探讨中医辨证论治科学性(3)
[5] 吴一龙.精准癌医学:走向未来的路[J].循证医学,2015, 15(1):1-2.
[6] 梅志刚,谭凌菁.从辨证论治看中医在我国精准医疗计划中的作为[J].中华中医药杂志,2016,31(10):3887-3890.
[7] 俞悦,周爱萍,曾益新.HER2阳性胃癌的治疗研究进展[J].中国肿瘤临床,2017,44(2):59-63.
[8] 王绍钧,王锐,朱冬波.实体瘤靶向药物的研究进展[J].中国药房, 2017,28(8):1149-1152.
[9] HYMAN D M, PUZANOV I, SUBBIAH V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J]. New England Journal of Medicine,2015,373(8):726-736.
[10] National Cancer Institute. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma (The MATCH Screening Trial)[EB/OL].(2015-06-08)[2017-07-17].https://www.clinicaltrials. gov/ct2/show/NCT02465060?cond=NCT02465060&rank=1.html.
[11] 陸兵.Ⅳ期肺腺癌初治患者的中医证型及临床特点分析[D].北京:北京中医药大学,2011.
(收稿日期:2017-10-11)
(修回日期:2018-11-21;编辑:梅智胜), 百拇医药(眭瑞卿 朱超林)
[6] 梅志刚,谭凌菁.从辨证论治看中医在我国精准医疗计划中的作为[J].中华中医药杂志,2016,31(10):3887-3890.
[7] 俞悦,周爱萍,曾益新.HER2阳性胃癌的治疗研究进展[J].中国肿瘤临床,2017,44(2):59-63.
[8] 王绍钧,王锐,朱冬波.实体瘤靶向药物的研究进展[J].中国药房, 2017,28(8):1149-1152.
[9] HYMAN D M, PUZANOV I, SUBBIAH V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J]. New England Journal of Medicine,2015,373(8):726-736.
[10] National Cancer Institute. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma (The MATCH Screening Trial)[EB/OL].(2015-06-08)[2017-07-17].https://www.clinicaltrials. gov/ct2/show/NCT02465060?cond=NCT02465060&rank=1.html.
[11] 陸兵.Ⅳ期肺腺癌初治患者的中医证型及临床特点分析[D].北京:北京中医药大学,2011.
(收稿日期:2017-10-11)
(修回日期:2018-11-21;编辑:梅智胜), 百拇医药(眭瑞卿 朱超林)